Clinical trials for Bladder / Urinary Tract / Urethral cancer

121 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Early Access Bladder / Urinary Tract / Urethral cancer

Accès précoce post-AMM– KEYTRUDA (Pembrolizumab)

Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive

1 recruiting site

Merck Sharp & Dohme LLC

Early Access Bladder / Urinary Tract / Urethral cancer

Accès précoce post-AMM - PADCEV (Enfortumab vedotin)

Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive

1 recruiting site

Astellas Pharma Développement mondial, Inc.

Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT05024773 #2024-512568-72-00

[PACLITAXEL-ACIDE HYALURONIQUE] Étude de l'ONCOFID-P-B

Non-invasive bladder cancer Urothelial carcinoma Localized 1 Surgery Immunotherapy

Systemic Treatment-Naive

5 recruiting sites

Fidia Farmaceutici s.p.a.

Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06510374

[ABLE-32] Essai comparatif du nadofaragène Firadenovec et de la simple observation chez des participants atteints d'un cancer de la vessie non invasif du muscle à risque intermédiaire

Non-invasive bladder cancer Urothelial carcinoma Localized None Surgery

10 recruiting sites

Ferring Pharmaceuticals

Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06545955

Essai évaluant le nadofaragène firadenovec intravésical seul ou en association avec une chimiothérapie ou une immunothérapie chez des patients atteints d'un cancer de la vessie non infiltrant le muscle de haut grade réfractaire au BCG.

Non-invasive bladder cancer Urothelial carcinoma Localized 1 Surgery Immunotherapy

Systemic Treatment-Naive

9 recruiting sites

Ferring Pharmaceuticals

Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT04620239 #2024-512322-28-00

[ENLIGHTED]Traitement endoluminal activé par la lumière du cancer urothélial des voies urinaires supérieures

Upper excretory tract cancer Urothelial carcinoma Localized None 1

2 recruiting sites

Steba Biotech S.A.

Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06919965

[MoonRISe-3] Étude évaluant le TAR-210 par rapport à la chimiothérapie intravésicale chez des participants atteints d'un cancer de la vessie non invasif du muscle à haut risque

Non-invasive bladder cancer Urothelial carcinoma Localized FGFR None 1 Immunotherapy

7 recruiting sites

Janssen

Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07129993 #2024-516906-47-00

[TROPION-Urothelial03] Étude du DATOPOTAMAB DERUXTECAN associé au CARBOPLATINE ou au CISPLATINE versus gemcitabine associée au carboplatine ou au cisplatine chez des participants atteints d'un carcinome urothélial localement avancé ou métastatique

Invasive bladder cancer Upper excretory tract cancer Urethral cancer Urothelial carcinoma Locally Advanced Metastatic 1 Immunotherapy Antibody Drug Conjugates (ADC)

Systemic Treatment-Naive

15 recruiting sites

Daiichi Sankyo

Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07106762 #2025-522400-24-00

[IZABRIGHT-Bladder01] Essai de phase 2/3 comparant l'IZALONTAMAB BRENGITECAN et la chimiothérapie à base de platine pour le cancer urothélial métastatique avec progression de la maladie pendant ou après l'immunothérapie

Invasive bladder cancer Urothelial carcinoma Metastatic 1 2 Immunotherapy

Chemotherapy Antibody Drug Conjugates (ADC)

10 recruiting sites

Bristol-Myers Squibb

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints de tumeurs solides avancées avec anomalies de MET - Cohortes C, D et F

Locally Advanced Metastatic MET 1 2 3 or more

BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1 Systemic Treatment-Naive Targeted therapy

5 recruiting sites

Apollomics